MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol MGTX. MeiraGTx Holdings filed confidentially on March 29, 2018. BofA Merrill Lynch, Barclays and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
